Donafenib Versus Sorafenib As First-Line Therapy In Advanced Hepatocellular Carcinoma: An Open-Label, Randomized, Multicenter Phase Ii/Iii Trial.
JOURNAL OF CLINICAL ONCOLOGY(2020)
摘要
4506Background: Sorafenib is still the standard first-line therapy for advanced hepatocellular carcinoma (HCC). Donafenib, a novel multikinase inhibitor, showed potential benefits in a previous pha...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络